COPD drug launch boosts AstraZeneca stock by 3%

Shares of AstraZeneca Pharma India increased 2.98%, reaching ₹6,588.35 on the BSE during Tuesday’s intraday trading. This surge followed the company’s announcement to launch Breztri Aerosphere in January 2025, marking a strategic move in the Indian pharmaceutical market. Analysts note this as a significant development, creating new opportunities for those looking to invest in stocks.

AstraZeneca’s regulatory approval for Breztri Aerosphere

On December 2, 2023, AstraZeneca Pharma India obtained import and market permission for Breztri Aerosphere from the Drugs Controller General of India. This drug is specifically designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

The company officially stated, "We are pleased to announce the launch of Breztri Aerosphere in January 2025. The medication aims to alleviate symptoms and prevent exacerbations in adult COPD patients."

Q2 performance highlights strong revenue growth

AstraZeneca Pharma India reported strong financial results for the second quarter of FY25. Key highlights include:

• Revenue growth: A 31% year-on-year increase, with Q2FY25 revenue from operations at ₹408 crore.
• First-half performance: Total revenue for the first half of FY25 reached ₹795.5 crore, driven by strong contributions from oncology, biopharmaceuticals, and rare disease segments.
• Profit recovery: Profit after tax (PAT) for Q2FY25 was ₹38.4 crore, a significant improvement from the ₹11.8 crore loss in Q1FY25. However, it reflected a 27% decline compared to the ₹52 crore PAT in the same period last year.

Share performance and market position

AstraZeneca Pharma’s stock has delivered strong returns:

• Year-to-date performance: The stock rose 16%, outperforming the BSE Sensex’s 8.2% rise.
• One-year gain: A 40% increase compared to the Sensex’s 18.8% growth.
• Valuation metrics: Shares trade at a price-to-earnings ratio of 195.24 times, with earnings per share at ₹32.77.

As of 10:43 AM, the stock slipped slightly, trading 2.50% higher at ₹6,557.75. The broader BSE Sensex declined 1.13% to 78,216.20.

Key takeaways

• AstraZeneca Pharma’s shares surged on the announcement of Breztri Aerosphere's launch, making it an appealing option to invest in stocks.
• The company’s Q2FY25 results highlight strong revenue growth, although PAT saw a year-on-year decline.
• AstraZeneca’s stock continues to outperform the market, showcasing its resilience and potential for investors.

For investors seeking opportunities in the pharmaceutical sector, AstraZeneca’s strategic moves offer promising avenues to invest in stocks.